Objective:

To synthesize evidence from pivotal trials to real-world applications regarding the efficacy and safety of efgartigimod in treating generalized myasthenia gravis (gMG).

Approach:

Key Findings:

• Efgartigimod showed rapid, clinically meaningful improvements in MG-ADL scores in AChR-Ab+ patients.
• The phase 3 ADAPT trial demonstrated a significant response rate of 68% in efgartigimod-treated patients compared to 30% in placebo.
• Long-term studies confirmed reproducible efficacy and sustained safety across multiple treatment cycles.
• Real-world evidence supports rapid response and steroid-sparing effects in various patient subgroups, including antibody-negative and thymoma-associated MG patients.

Interpretation:

Limitations:

• Comparative efficacy against other novel biologics is still under investigation.
• Long-term effects and optimal patient selection require further research.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.